Biotech readiness review: users guide

Is your biotech building an asset investors will compete to fund?

Promising science is the starting point. A compelling investment case requires more: defensible intellectual property, evidence of differentiation, a credible development pathway and a clear route to capturing commercial value.

Steer helps biotech founders identify what may strengthen, or weaken, their investment case before fundraising pressure limits their options.

Start with a free, five-minute review.

Begin my free biotech review

The case

What makes a biotech investment case compelling?

Investors do not evaluate scientific promise in isolation. They need to understand what the company has built, what remains uncertain, why the opportunity is defensible and how additional capital will create value.

  1. 1
    Intellectual property and competitive protection

    Does your IP strategy protect the features that create your competitive advantage? Patents can establish barriers to competition, support licensing opportunities and strengthen an investment case. Their value, however, depends on claim scope, ownership, status, geographic coverage and commercial relevance. The question is not simply whether you have filed a patent. It is whether your protection strategy helps the company capture value and defend its position.

  2. 2
    Differentiation and evidence

    What makes your technology or product meaningfully better than existing alternatives? A novel mechanism or promising preclinical result is not, by itself, proof of a sustainable advantage. Investors need to understand what has been demonstrated, what remains a hypothesis and how the next stage of evidence generation will reduce uncertainty.

  3. 3
    Development pathway and value inflection

    What must the company demonstrate next, and what will it take to get there? The development plan should connect the scientific and clinical milestones, timelines, capital requirements and key uncertainties. The next financing should support progress towards meaningful evidence or a milestone that strengthens the company's strategic position.

  4. 4
    Regulatory, clinical and adoption strategy

    Is there a credible pathway from the current stage to a product that can be used in practice? That means understanding the relevant development and regulatory requirements, the evidence needed to support the intended use, and the factors that could influence adoption, prescribing, reimbursement or partnering. A promising product without a realistic route to adoption may be difficult to finance. A clear development pathway is valuable, but it must be supported by a differentiated asset and a credible commercial opportunity.

  5. 5
    Market position and value capture

    Can your company capture meaningful value from the opportunity it is pursuing? A large total addressable market does not automatically make a strong investment case. Investors need to understand the initial market, the competitive alternatives, the barriers to entry and the company's ability to access customers or partners. A defensible niche with a credible route to expansion can be more compelling than a large market supported by assumptions the company cannot substantiate.

  6. 6
    Financing strategy and investment case

    Does your plan explain why additional capital is needed, what it will achieve and how the resulting milestones could strengthen the company's value? The pitch deck should communicate the investment case, not substitute for one. Strong presentation matters, but it cannot compensate for unresolved strategic weaknesses.

What you receive

Your score, then your plan.

Your readiness score

Complete the review and see your score immediately. Use it as a structured starting point for understanding where your investment case may need further attention.

It is not a prediction of whether you will receive funding.

A customised action plan within 24 hours

Our team reviews your responses and prepares a human-led action plan identifying the priorities that could strengthen your investment case.

The plan is intended to help you understand:

  • Which areas deserve attention first.
  • Why those areas matter to investors.
  • What evidence, analysis or strategic work may be needed.
  • Which actions may require longer-term planning rather than an immediate fix.

The recommendations are based on your responses. The review does not replace a full scientific, clinical, regulatory, legal or financial diligence exercise.

The review and initial action plan are free at present. There is no obligation to purchase advisory services.

Begin my free biotech review

Timing

When should you take the review?

Ideally, before you need to raise.

If you intend to close a financing round in 12 to 18 months, now may be the time to identify the IP, evidence, development or commercial priorities that need to be addressed.

Waiting until you have only three to six months of runway can leave too little time to strengthen your position. Patent strategy, evidence generation, development planning and market validation may require substantial lead time.

The right preparation period depends on your development stage, financing requirements and next value-inflection milestone. The objective is to create more options before time pressure forces compromises.

You do not need to be preparing a Series A today. You need to be building a company that will be ready when the right financing opportunity arrives.

How it works

Four steps.

  1. 1

    Complete the review

    Answer the questions about your company's investment readiness. The review is designed to take about five minutes.

  2. 2

    See your score

    Review your results immediately and identify the areas that may require attention.

  3. 3

    Receive your action plan

    Within 24 hours, our team reviews your responses and sends your customised action plan.

  4. 4

    Decide what to do next

    Use the plan independently or, if you wish, discuss potential next steps with us. There is no obligation to engage us.

Confidentiality

A note on confidentiality.

The review is designed to evaluate your strategic position without requiring disclosure of unpublished scientific findings, invention details or trade secrets.

Please do not enter confidential technical information into your answers. Before submitting personal or company information, review our privacy policy to understand how it is collected, used and retained.

Frequently asked questions

Questions biotech founders ask.

Is the review free?

Yes. The review and the initial human-led action plan are free at present.

Will I receive only a score?

No. Your score is available immediately, and our team will send a customised action plan within 24 hours.

Does a high score mean my company will raise successfully?

No. The review is a structured reading of your responses, not a funding prediction. Investment outcomes depend on many factors, including the quality of the opportunity, evidence, team, financing environment and investor requirements.

What if my score is low?

A lower score should be treated as an indication that certain areas may need attention, not as a verdict on the company's potential. The action plan is intended to help you identify priorities and determine what to do next.

Do I need to have a patent filed?

Not necessarily. The relevant question is whether your company has a credible strategy for protecting its competitive advantage. Depending on the business, this may involve patents, know-how, trade secrets, licensing rights or other forms of protection. The appropriate approach depends on the asset and commercial strategy.

Do I need to be close to Series A?

No. The review can help founders at different stages identify priorities for building a stronger investment case. The specific actions will depend on the company's development stage and objectives.

Will Steer expect me to purchase advisory services?

No. The initial review and action plan are free at present, with no obligation to purchase further services.

Begin

Build the investment case before you need the investment.

Start with a free, five-minute biotech review.

Begin my free biotech review